That is probably true AB. However....
There may be restrictions on sale in the destination (the U.S. for example where the FDA takes a dim view).
There may be export or import issues (would be the case for commercial quantities in Oz) and TGA issues here.
So you have a fairly highly taxed product as your cost base, quite likely added taxes in the destination and the likelihood that the product will be released in the destination at a lower price than your cost price.
Not good!
Ann: VIRALEZE now launched by LloydsPharmacy in the UK, page-47
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $38.11K | 389.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20455 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 38876 | 3 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |